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Background: We recently showed that LOH proximal to M6P/IGF2R locus (D6S1581) in primary ovarian tumors is
predictive for the presence of disseminated tumor cells (DTC) in the bone marrow (BM). For therapy-monitoring, it
would be highly desirable to establish a blood-based biomarker. Therefore, we quantified circulating DNA (cirDNA)
in sera of 63 ovarian cancer patients before surgery and after chemotherapy, measured incidence of LOH at four
cancer-relevant chromosomal loci, correlated LOH with tumor cell spread to the BM and evaluated prognostic
significance of LOH.
Methods: cirDNA was fractionated into high- and low molecular-weight fraction (HMWF, LMWF) for LOH-profiling,
utilizing PCR-based fluorescence microsatellite analysis. BM aspirates were analyzed for DTC by
immunocytochemistry using the pan-cytokeratin antibody A45-B/B3.
Results: cirDNA levels in the HMWF before surgery were predictive for residual tumor load (p = 0.017). After
chemotherapy, we observed a significant decline of cirDNA in the LMWF (p = 0.0001) but not in the HMWF.
LOH was prevalently detected in the LMWF with an overall frequency of 67%, only moderately ablating after
chemotherapy (45%). Before surgery, LOH in the LMWF at marker D10S1765 and D13S218 significantly correlated
with tumor grading and FIGO stage (p = 0.033, p = 0.004, respectively). In both combined fractions, LOH at D6S1581
additionally associated with overall survival (OS) (p = 0.030). Moreover, solely LOH at D10S1765 in LMWF after
therapy correlated with DTC in BM after therapy (p = 0.017).
Conclusion: We demonstrate the applicability and necessity of DNA-fractionation prior to analyzing circulating
LOH and identify LOH at D10S1765 and D6S1581 as novel blood-based biomarkers for ovarian cancer, being
relevant for therapy-monitoring.
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genesBackground
Epithelial ovarian cancer accounts for most tumor-
related deaths among female malignancies [1]. At the
time of primary diagnosis, 70% of the ovarian cancer
patients have advanced tumor stages. Although there are
high response rates to carboplatin–based chemotherapy,* Correspondence: jandominik.kuhlmann@uk-essen.de
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Standard treatment of advanced ovarian cancer is pri-
mary surgery aiming at macroscopic complete tumor re-
section and subsequent platinum- and paclitaxel-based
chemotherapy [2]. Residual postoperative tumor burden
is one of the most important prognostic factors in ovar-
ian cancer [3]. However, despite advances in treatment
strategies, more than 50% of all patients will experience
recurrence [4], resulting in worse prognosis. Innovative
therapy approaches are therefore needed to improve the
patient’s outcome.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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markers is of high interest. We previously analyzed pri-
mary ovarian tumors for loss of heterozygosity (LOH)
incidence at a panel of four microsatellite markers asso-
ciated with ovarian cancer-relevant tumor suppressor
genes involved in apoptosis, platinum sensitivity and
DNA-repair, namely PTEN (marker D10S1765), BRCA1
(marker D13S218), BRCA2 (marker D17S855) and M6P/
IGF2R (D6S1581). We revealed that LOH incidence in
the primary tumor at marker D6S1581 (directed prox-
imal to M6P/IGF2R locus) is predictive for the presence
of disseminated tumor cells (DTC) in the bone marrow
(BM) before surgery and after chemotherapy [5]. How-
ever, primary tumor tissue is only available by resection,
and it would be highly desirable to establish a blood-
based biomarker which is suitable to monitor the course
of disease. In this regard, cell-free nucleic acids, detect-
able in the blood [6,7], could serve as a tool to detect
and characterise residual tumor load [8]. It was denoted,
that cancer patients harbor higher concentrations of cir-
DNA in their blood than normal healthy donors [7] and
already in the 1980s, it was suggested that cirDNA in
the circulation of cancer patients might originate from
malignant cells [9,10]. Up to now, a variety of tumor
specific alterations like T790M EGFR mutations in lung
cancer [11] could be detected in cirDNA of cancer
patients. Previous studies on allelic loss in serum of can-
cer patients usually analyzed non-fractionated cirDNA,
which is largely diluted by contaminating normal DNA
and thus, a broad range of LOH detection rates with
partly contradictory results was observed [12-14]. In a
recently published study on prostate cancer, we could
technically improve sensitivity of LOH detection in cir-
DNA by a sequential purification procedure with two
different column systems in order to fractionate cirDNA
into high-molecular-weight fraction (HMWF) and low-
molecular-weight fraction (LMWF) [15]. However, for
ovarian cancer, no data on circulating allelic loss exist so
far. Therefore, in the present study, we intended to ex-
tent our previous LOH investigation from the primary
tumor to the patient’s blood sera obtained at primary
diagnosis and after chemotherapy, utilizing a DNA frac-
tionation technique [15]. The purpose was to monitor
levels of cirDNA, to describe incidence and pattern of
LOH at four ovarian cancer-relevant chromosomal loci,
to correlate LOH occurrence with tumor cell spread to
the BM and finally to evaluate prognostic significance of
LOH in the blood of ovarian cancer patients.
Methods
Characterisation of study patients
The present study was conducted at the Department of
Gynecology and Obstetrics at the University Hospital in
Essen. Patients with primary epithelial ovarian cancerwere enrolled from February 2001 until November 2007.
In total, sera of 63 ovarian cancer patients and sera of 20
healthy donors were studied. Overall survival (OS) data
of these patients were obtained from the local municipal
registry. The median follow-up time was 3.04 years, ran-
ging from 0.08 to 5.83 years. Informed written consent
was obtained from all patients, and the study was
approved by the Local Essen Research Ethics Commit-
tee (05/2856). Clinical data of the patients are summar-
ized in Table 1. Radical tumor debulking was performed
when feasible. Radical pelvic and para-aortic lymphade-
nectomy was performed, if macroscopic complete
tumor resection was achieved. Chemotherapy consisted
of six cycles of carboplatinum (AUC 5) and paclitaxel
(175 mg/m2). Grading was performed according to
WHO classification. Patients who had a treatment-free
interval of 0–5 months after first-line chemotherapy can
appropriately be considered to have clinically defined
platinum resistant disease.
Preparation of blood serum
Nine ml blood were drawn from each patient, stored at
4°C and processed within 4 h to avoid blood cell lysis.
Blood fractionation was carried out by centrifugation for
10 min at 2500 g. Subsequently, 3 – 4 ml of the upper
phase, constituting blood serum, were removed and sub-
jected to isolation of cirDNA.
DNA extraction and fractionation
As described previously [15], DNA of the HMWF was
extracted using the QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany). Subsequently, the flow-through from
the Qiagen columns was mixed with 2 volumes of 6 M
guanidine thiocyanate and purified on Wizard Plus col-
umns (Promega, Mannheim, Germany) to obtain the
LMWF. Genomic DNA from matching paraffin embed-
ded tumor-free lymph nodes (reference DNA) was
extracted using the QIAamp Blood DNA Mini Kit (Qia-
gen). Quantity and quality of the extracted DNA were
determined spectrophotometrically using the NanoDrop
Spectrometer ND-1000 (NanoDrop, Delaware, USA). All
steps were performed according to the manufacturer’s
instructions.
Fluorescence-labeled PCR
DNA was selectively amplified by PCR reaction using
primer pairs binding to microsatellite markers of inter-
est, previously described by us in detail [5]. PCR condi-
tions were: 10 ng of DNA were amplified in a 10-μl-
reaction containing PCR Gold buffer (150 mM Tris–
HCl, pH 8.0 and 500 mM KCl), 2.5 mM MgCl2 (Applied
Biosystems, Mannheim, Germany), 200 μM dNTPs
(Roche, Mannheim, Germany), 0.2 μM of primer sets
(Sigma, Taufkirchen, Germany) and 0.5 U AmpliTaq
Table 1 Patient Characteristics at the Time of Primary
Diagnosis of Ovarian Cancer
Patients (%)
Total 63
Age 58 years (range 21 – 81 years)
Tumor stage
FIGO I-II 13 (20.6)
FIGO III 35 (55.6)






I - II 31 (49.2)




other subtypes 13 (20.6)
Residual tumor
macroscopic
complete resection 30 (47.6)
any residual tumor 33 (52.4)
Survival
OSa 36.5 months (range 1 – 70 months)
Alive 28 (44.4)
Dead 34 (54.0)
DFSb 12 months (range 6 – 48 months)
no relapse 18 (28.6)
relapse 45 (71.4)
Platinum Resistance
Platinum sensitive 54 (85.7)
Platinum resistant 9 (14.3)
DTCc








cDTC, disseminated tumor cells in BM.
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primers were fluorescence-labeled (HEX, FAM or
TAMRA) at the 5' end. The reaction was initialised by
heat-activation of the DNA polymerase (10 min at 95°C)
followed by 40 cycles of PCR amplification. Tetramethy-
lammonium chloride (TMAC) at a final concentration
of 0.1 mM was added to the PCR reaction. As previously
shown, the addition of TMAC increases the yield of
PCR products, enhances specificity and decreases the
probability of primer dimerisation, formation of slippage
peaks and artificial LOH [15-17].Evaluation of PCR products
The fluorescence-labeled PCR products were separated
by capillary gel electrophoresis and detected on an auto-
mated Genetic Analyzer 310 (Applied Biosystems, Ger-
many). Fragment length and fluorescence intensity were
evaluated by the GeneScan software. The 500-ROX size
marker (Applied Biosystems) served as an internal
standard. LOH incidence was determined by calculating
the ratio of intensities of the two alleles from a tumor
sample corrected by that from the corresponding tumor-
free lymph node sample (reference DNA). Shift in allelic
ratio was interpreted as LOH if the final quotient was≤
0.6 or> 1.67. All experiments were performed in dupli-
cates, homozygous and non-analyzable peaks were desig-
nated as non-informative cases. Previously, dilution
experiments were performed to calculate the lowest por-
tion of tumor-specific DNA that could be detected. For
this purpose, known proportions of normal DNA
(derived from leukocytes) and tumor DNA were mixed
and amplified [15]. All experiments were performed in
triplicates. LOH positivity for a respective sample was
exclusively considered valid in case of two independently
obtained LOH-positive results. Homozygous and non-
analyzable peaks as well as sample triplets with any fur-
ther indication for amplification abnormality (e.g. strong
intra-triplicate peak-ratio fluctuation or low fluorescence
level) were designated as non-informative.Collection and analysis of BM
BM was bilaterally aspirated from the anterior iliac
crests of 53 primary ovarian cancer patients before sur-
gery and of 40 patients after chemotherapy (local anaes-
thesia with mepivacain), respectively and processed
within 24 hours. Tumor cell isolation and detection
were performed based on the recommendations for
standardized tumor cell detection published by the
German Consensus Group of Senology [18]. In total,
8 x 106 mononuclear cells (MNC) per patient were
analyzed. The slides were air-dried overnight at room
temperature.
p = 0.0001
Figure 1 Quantification of fractionated serum DNA derived
from ovarian cancer patients. The box plot shows the results of
spectrophotometrical quantification of cirDNA in the HMWF and the
LMWF derived from blood serum of ovarian cancer patients before
surgery and after chemotherapy. Statistical significance according to
the Mann–Whitney-U test for the non-parametric comparison of two
independent variables is indicated.
Kuhlmann et al. BMC Cancer 2012, 12:325 Page 4 of 9
http://www.biomedcentral.com/1471-2407/12/325Immunocytochemistry
Staining for CK-positive cells was performed using the
murine monoclonal antibody Mab A45-B/B3 (Micromet,
Munich Germany), directed against a common epitope
of CK polypeptides including the CK heterodimers 8/18
and 8/19. This standard procedure for detection of DTC
has been described in detail elsewhere [5,18,19].
Evaluation of CK+Cells
Microscopic evaluation of the slides was carried out
using the ARIOL system (Applied Imaging) according to
the International Society for Hematotherapy and Graft
Engineering (ISHAGE) evaluation criteria and the DTC
consensus [18,19]. These automated scanning micro-
scopes and image analysis systems consist of a slide
loader, camera, computer and software for the detection
and classification of cells of interest, based on particular
colour, intensity, size, pattern and shape.
Statistical analysis
Statistical analysis was performed using the SPSS soft-
ware package, version 18.0 (SPSS Inc. Chicago, IL). The
chi Square or two-tailed Fischer’s exact test and the
univariate binary logistical regression were used to
identify associations between LOH patterns in the
patient’s sera and clinicopathological parameters of
ovarian cancer patients including DTC in the BM. In
addition, the Mann–Whitney–U and the Wilcoxon-W
tests for non parametric comparison of two independ-
ent and dependent variables were used, respectively.
Kaplan-Meier plots were used to estimate OS and re-
currence. The log rank test was used for statistical ana-
lysis. A p-value ≤ 0.05 was considered statistically
significant. All p-values are two-tailed.
Results
Quantification of cirDNA in blood serum of ovarian
cancer patients and its clinical relevance
From a total number of 63 patients before surgery, 58
sera after chemotherapy were available and subjected to
isolation of cirDNA, which was fractionated into HMWF
and LMWF. In the HMWF, before surgery, a median
DNA concentration of 640 ng/ml of serum (range 30 –
2460 ng/ml) was recorded, whereas after chemotherapy,
a median DNA content of 660 ng/ml (range 60 –
2820 ng/ml) could be detected (Figure 1). Serum DNA
concentrations before surgery and after chemotherapy
were similar, albeit the concentration after chemotherapy
had an increased distribution. In the LMWF, before sur-
gery, a median value of 810 ng/ml (range 40 – 2060 ng/
ml) was detected. After chemotherapy, we observed a
highly significant decline of DNA content in the LMWF
to a median value of 380 ng/ml (range 40 – 1790 ng/ml)
(p = 0.0001). Using the Mann–Whitney-U test, statisticalevaluation showed that DNA concentration in the
HMWF before therapy significantly associated with re-
sidual tumor load left after surgery (p = 0.017).LOH frequency and distribution in blood serum of
ovarian cancer patients
All sera of ovarian cancer patients, obtained before sur-
gery and after chemotherapy, were tested for LOH at
four ovarian cancer-relevant microsatellite markers, pre-
viously described by us in detail [5]. Before Surgery, 31/
63 patients (49%) showed at least one LOH in one of the
two fractions, whereas after chemotherapy in 24/58
patients (41%), at least one LOH was detectable. The
presence of LOH could not be observed in cirDNA of
healthy donors (data not shown). Frequency and distri-
bution of LOH incidence are graphically depicted in Fig-
ure 2. In the HMWF, LOH was a rare event with an
overall detection rate of 13% before surgery and 21%
after chemotherapy, whereas in the LMWF, LOH oc-
curred more frequently with an overall detection rate of
67% before surgery and 45% after chemotherapy. Allelic
loss at D6S1581 before surgery and after chemotherapy
was most prevalent in both cirDNA fractions and gener-
ally, LOH incidence in the LMWF at all markers tended
to moderately decrease after chemotherapy. By compar-
ing the incidence of LOH at all four markers in both cir-
DNA fractions before surgery and after chemotherapy,
we denoted that in 25/63 patients (40%), LOH for at
least one marker was not detectable anymore after
chemotherapy. In 6/63 patients (10%), LOH for at least
one marker was concordantly detected before surgery
and after chemotherapy, whereas “de novo” occurrence
of LOH after chemotherapy was observed in 19/63
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Figure 2 LOH incidence in blood serum at ovarian cancer-related chromosomal regions. The bar chart graphically demonstrates the LOH
frequencies observed in the HMWF- and LMWF-DNA of blood serum from ovarian cancer patients at four selected microsatellite markers.
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DTC in the BM
In total, DTC were studied in 53/63 patients before sur-
gery and in 40/58 patients after chemotherapy. Prior to
surgery, DTC were detected in 26/53 patients (49%) with
a median number of 6 cells per 8 x 106 MNC (range 1–
38 cells). After chemotherapy, 20/40 patients (50%)
revealed DTC in their BM with a median number of 10
cells per 8 x 106 MNC (range 1–35 cells). LOH inci-
dence at marker D10S1765 in HMWF after chemother-
apy significantly correlated with the incidence of DTC
after therapy (p = 0.017) (Additional file 1: Table S1).p = 0.030
Figure 3 Correlation of LOH at D6S1581 and overall survival.
Kaplan-Meier curves depict overall survival analysis of patients with
and without LOH incidence at marker D6S1581 in a combined
analysis of both fractions, before surgery. Top curves, patients with
retention of the two alleles at D6S1581. Bottom curves, patients with
LOH at marker D6S1581.Clinical significance of LOH in blood serum
Correlation of LOH incidence in cirDNA with common
clinicopathologic parameters was performed (Additional
file 1: Table S1). Before surgery, LOH at marker
D10S1765 in HMWF and D13S218 in LMWF and in
both combined fractions significantly correlated with
FIGO stage (p = 0.035, p = 0.033, p = 0.012, respectively).
Moreover, LOH at chromosomal site D10S1765 in
LMWF and in both combined fractions correlated with
tumor grading (p = 0.004, p = 0.012, respectively). How-
ever, no association of LOH with platinum resistance
could be observed.
Median disease-free survival (DFS) of the patients was
12 months (range 6 – 48 months) and median OS was
36.5 months (range 1–70 months). As illustrated in Fig-
ure 3, LOH at D6S1581 in both combined fractions was
predictive for a reduced OS (p = 0.030). Median OS peri-
ods were 25 and 53 months (95% CI 22–28 and 28–78)
in patients who displayed LOH and no LOH at D6S1581
in their serum, respectively. However, no correlation of
LOH at the investigated chromosomal regions and DFS
of the patients was observed.Discussion
In the current study, we show that fractionation of DNA
is highly essential for reliable detection of LOH in serum
samples of ovarian cancer patients. Applying this new
technique, we found more LOH in the LMWF than in
the HMWF indicating that tumor-associated DNA is ra-
ther short-stranded than long-stranded. This observation
is also supported by the fact that after chemotherapy,
only the LMWF-DNA levels decreased, whereas the
HMWF-DNA levels were similar prior to surgery and
after chemotherapy. Moreover, our key findings showed
that LOH at D6S1581 before surgery is predictive for
reduced OS (combined fraction analysis) and LOH at
D10S1765 after chemotherapy was significantly asso-
ciated with tumor cell spread to the BM, respectively.
It has been reported that tumor-associated DNA,
released into circulation, is rather of fragmented and
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was proposed that tumor cells, which proliferate at ab-
normal rates, frequently undergo apoptosis [21-23] and
cumulatively deliver small and fragmented DNA into the
circulation. Therefore, it seems reasonable that the
observed decline of cirDNA in our patients, selectively
observed in the LMWF, can be ascribed to a systematic
clearance of tumor cells upon chemotherapy, which
leads to a global reduction of low molecular weight
DNA. However, we did not see any significant change of
HMWF-DNA prior to surgery and after chemotherapy.
Long-stranded HMWF-DNA could contain an excess of
normal DNA in the circulation and derives from normal
blood lymphocytes [24,25], or necrotic stromal and in-
flammatory cells within the tumor microenvironment
[26]. Accordingly, the observed steady-state HMWF-
DNA content before surgery and after chemotherapy
might indicate that chemotherapy does not sustainably
affect HMWF-DNA in blood of ovarian cancer patients.
The majority of allelic losses were detected in the
LMWF and also significantly correlated with common
clinicopathological parameters of the patients whereas in
the HMWF, LOH constituted a comparatively rare event.
So far, previous studies on several tumor entities exclu-
sively analyzed non-fractionated cirDNA and thus, there
is a broad variety of LOH detection rates with partly
contradictory results [12,24]. In cooperation with the la-
boratory of Schwarzenbach et al., we engaged its newly
developed fractionation technique and could show that
our findings were in accordance with data on prostate
cancer, which showed a higher LOH detection rate in
the LMWF compared to the HMWF [15]. To date, with
the exception of this study, there is no further investiga-
tion of LOH on fractionated cell-free DNA. However,
Wang et al. used a column-based, modified Guanidine/
Promega Resin (G/R) method to selectively isolate frag-
mented DNA and showed for colorectal cancer patients
that preferential isolation of fragmented DNA enhances
the detection of circulating mutated K-RAS DNA
sequences [20]. In this context, Wang proposed that in
order to enhance the detection rate of somatic muta-
tions or epigenetic modifications in circulating blood
DNA, a method selectively extracting small DNA frag-
ments should be used. Given these considerations and
comprising our data, we can conclude for ovarian cancer
that tumor DNA is rather reflected in the LMWF.
In comparison to preoperative sera, LOH incidence
only moderately decreased after chemotherapy. Tracing
microsatellite alterations in follow-up sera of patients
with different cancer entities and investigating their
clinical significance has previously been described in
several studies [27,28]. In a previous investigation on
breast cancer, overall LOH pattern of serial serum
DNA samples was largely stable but it remained unclearif the remaining non concordant results were due to
changes in clinical status [29]. In another study, the
persistence of microsatellite alterations in plasma DNA
of post-mastectomy patients has been associated with
bad-prognosis histological parameters and indicated
micrometastatic disease [30]. The detection of tumor
associated microsatellite alteration after accomplished
chemotherapy could indicate the presence of residual
primary tumor or occult micrometastatic cells, such as
circulating tumor cells or DTC, being resistant to
treatment.
Apart from patients who’s LOH vanished upon che-
motherapeutic intervention, a subset of patients dis-
played LOH events after chemotherapy which were not
detectable before surgery. This observation has also been
described in small cell lung cancer patients (SCLC). In
case of a successful therapy, molecular alterations on
cell-free DNA concomitantly vanished and new LOH
events after chemotherapy coincided with disease recur-
rence [31]. A statistically substantiated conclusion about
the prognostical impact of “de novo” LOH occurrence
after chemotherapy in our patient cohort cannot be per-
formed based on the limited number of this patient
group. However, one can conceptually speculate that a
certain subset of cancer cells with stem like properties is
not affected by cytoreductive treatment, might evolve by
clonal evolution, might systematically acquire de novo
genetic alterations and might become capable of effect-
ing recurrence. Accordingly, it could be observed previ-
ously that a side population of tumor cells with stem cell
features, overexpressing ABC drug transporters, sus-
tained the growth of drug-resistant ovarian tumors and
induced recurrence [32].
Considering LOH at the different loci, we observed
that LOH at D10S1765 in LMWF after therapy was
predictive for tumor cell dissemination to BM after
therapy, FIGO stage and tumor grading. Significant
associations of this marker with FIGO stage and grad-
ing coincide with our previous LOH investigation in
primary ovarian tumor tissue [5]. D10S1765 is located
at chromosomal band 10q23.3. This region encodes for
PTEN, a dual-specificity protein phosphatase antagoniz-
ing the PI3K-Akt signaling pathway and regulating cel-
lular proliferation, DNA repair, stem cell self-renewal,
genomic instability and metastasis [33]. Particularly, in
ovarian cancer, PTEN down-regulation has been shown
to be functionally involved in platinum resistance [34].
It seems rational that highly advanced tumors are more
dependent on the accumulation of genetic alterations
than early-stage neoplastic lesions. Furthermore, it can
be hypothesized that PTEN locus disruption by LOH,
in combination with other inactivation mechanisms
such as epigenetic events [35], might functionally be
involved in tumor progression, persistence of tumor
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ate to the BM.
We revealed that LOH in cirDNA of ovarian cancer
patients is predictive for FIGO stage and tumor grading.
Moreover, one of our key finding was that LOH at mar-
ker D6S1581 in a combined analysis of both fractions,
detected at primary diagnosis, was predictive for reduced
OS. Microsatellite marker D6S1581 is located at 6q25.1,
25 kb proximal to the mannose 6-phosphate/insulin-like
growth factor II receptor (M6P/IGF2R) locus [36]. This
receptor is well described in breast cancer [37-39] and is
supposed to act as a tumor suppressor gene by nega-
tively regulating cell survival, tumor invasion and metas-
tasis [40]. Moreover, LOH at M6P/IGF2R is well known
to be a frequent event in primary ovarian cancers [41]
and a low D6S1581 copy number was associated with
platinum-resistant condition in ovarian cancer [36].
However, in our patient cohort, LOH occurrence did not
significantly associate with platinum resistance. Gener-
ally, advanced ovarian cancer is a relatively chemo-
sensitive tumor with overall clinical response rates of 70
– 80% [42]. Therefore, the observed number of resistant
cases in our study (14.3%) might be too limited to allow
a reliable and statistical substantiated conclusion.
The ascertained prognostic impact of marker D6S1581
in cirDNA of ovarian cancer patients in our current
study is of particular interest, as our present serum data
corroborate our previous findings on ovarian tumor tis-
sue showing that allelic loss at D6S1581 is a biomarker
for tumor cell spread to the BM [5]. Thus, evidence is
accumulating, that genomic region proximal to M6P/
IGF2R locus seems to be functionally implicated for
ovarian tumorigenesis and may serve as a blood-based
biomarker for prognosis. These data clearly sustain the
reliability of cell-free cirDNA as “real-time liquid bi-
opsy”, providing valuable prognostic information and
being accessible non-invasively. Moreover, most of the
significant associations with the clinicopathological para-
meters were found at the time of primary diagnosis be-
fore surgery. Thus, preoperative serum seems to
constitute most informative reading point for patients
with primary ovarian cancer.
The occurrence of artificial LOH in the LMWF, which
is supposed to be random allelic loss due to low DNA
concentration or impaired DNA integrity, constitutes a
possible draw-back in the context of low-molecular-
weight DNA amplification. However, random allelic loss
due to a suboptimal DNA integrity would logically be
accompanied by a statistically more frequent loss of the
“shorter” allele of a polymorphic microsatellite maker,
which should be more difficult to amplify than the
“longer” allele. Despite from the addition of TMAC in
order to prevent artificial LOH and to improve amplifi-
cation condition, we found the number of losses of“short” and “long” alleles being well balanced throughout
the entire marker panel and throughout all patients.
Thus, it is very unlikely that observed LOH in the
LMWF reflect a random process.
We previously tried to characterize fragment size dis-
tribution of HMWF and LMWF [15], but, however, due
to our experimental conditions and due to a partly over-
lapping performances of the different filter-column sys-
tems, so far, it was not possible to narrow down an exact
cut-off for cirDNA fractionation. In this context, further
studies are planned to better characterize size distribu-
tion of cirDNA fractions.
Conclusively, in the present study, we demonstrate the
applicability and necessity of DNA fractionation in order
to selectively monitor tumor associated microsatellite
alterations in blood serum of ovarian cancer patients.
Given our present findings, tumor DNA seems to be
mostly reflected in the LMWF. It is of note that tumor
specific circulating LOH with diagnostic relevance is not
exclusively limited to the LMWF. Based on our findings,
we have to consider that the HMWF might also contain
a certain proportion of tumor derived DNA and should
additionally be analyzed for blood-based LOH studies on
ovarian cancer. Moreover, we newly identified LOH at
D10S1765 and D6S1581 as novel blood-based biomar-
kers for tumor cell spread to the BM and prognosis, re-
spectively, which might be of clinical relevance for
monitoring studies. Genomic region proximal to M6P/
IGF2R, a promising target, and its role in ovarian cancer
is currently under investigation.
Conclusion
We demonstrate the necessity and applicability of DNA-
fractionation prior to analyzing circulating allelic loss in
the blood of ovarian cancer patients. Moreover, we iden-
tified novel circulating biomarkers and sustain diagnostic
impact of cirDNA in terms of a “real-time liquid
biopsy”.
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